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Background: The use of newly developed mixed-dilution hemodiafiltration (HDF) can supplement the weaknesses of pre- and postdi-
lution HDF. However, it is unclear whether mixed-HDF performs well compared to predilution HDF. 
Methods: We conducted a prospective, open-labeled, randomized controlled trial from two hemodialysis centers in Korea. Between 
January 2017 and September 2019, 60 patients who underwent chronic hemodialysis were randomly assigned at a 1:1 ratio to re-
ceive either predilution HDF (n = 30) or mixed-HDF (n = 30) for 6 months. We compared convection volume, changes in small- and 
medium-sized molecule clearance, high-sensitive C-reactive protein (hs-CRP) level, and dialysis-related parameters between the two 
dialysis modalities. 
Results: A mean effective convection volume of 41.0 ± 10.3 L/session in the predilution HDF group and 51.5 ± 9.0 L/session in the 
mixed-HDF group was obtained by averaging values of three time-points. The difference in effective convection volume between the 
groups was 10.5 ± 1.3 L/session. This met the preset noninferiority criteria, suggesting that mixed-HDF was noninferior to predilution 
HDF. Moreover, the β2-microglobulin reduction rate was greater in the mixed-HDF group than in the predilution HDF group, while 
mixed-HDF provided greater transmembrane pressure. There were no significant between-group differences in Kt/V urea levels, 
changes in predialysis hs-CRP levels, proportions of overhydration, or blood pressure values. Symptomatic intradialytic hypotension 
episodes and other adverse events occurred similarly in the two groups. 
Conclusion: Use of mixed-HDF was comparable to predilution HDF in terms of delivered convection volume and clinical parameters. 
Moreover, mixed-HDF provided better β2-microglobulin clearance than predilution HDF.  
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Introduction 
Remarkable technical advances have been made with re-
gard to dialysis membranes and hemodialysis (HD) ma-
chines in recent decades. In spite of such improvements, 
mortality rates remain high, and the overall 5-year survival 
rate in patients of kidney failure with replacement therapy 
(KFRT) is 30% in the United States [1]. Unfortunately, dialy-
sis treatment alone cannot improve clinical outcomes, and 
a comprehensive approach is required. Such an approach 
should include blood pressure control, appropriate body 
fluid control, elimination of middle-sized molecules, remov-
al of inflammatory substances, osteoporosis and anemia 
management, and the provision of sufficient nourishment. 
Hemodiafiltration (HDF) can facilitate the achievement of 
these diverse goals [2–5]. In fact, HDF has many advantages 
over conventional HD, which include its higher clearance 
of low and middle molecules and inflammatory cytokines, 
improvement of anemia, and maintenance of hemodynamic 
stability [6,7]. Notably, recent clinical trials have shown that 
HDF increased patient survival rates compared to conven-
tional HD, especially in patients who received high-volume 
convective therapy [7,8]. 
There are two representative HDF modes: pre- and postdi-
lution. Each has strengths and limitations. Postdilution HDF 
is the most effective way to maximize molecule clearance. 
However, blood concentrations can be elevated using HDF, 
which can cause thrombosis. On the other hand, predilution 
HDF can resolve this problem [9] but requires about three 
times more purified water than postdilution HDF and does 
not guarantee maximal clearance. Therefore, the use of 
mixed-HDF emerged to compensate for the shortcomings 
of the other two HDF modalities [10,11]. In mixed-HDF, the 
substitution fluid required for dialysis is injected at both the 
entrance and exit of the dialysis membrane. Using a contin-
uous monitoring and feedback system to assess transmem-
brane pressure (TMP) in the dialyzer, dialysis is automati-
cally switched to either pre- or postdilution HDF mode and 
optimizes TMP during HD [12]. Despite these advantages 
of mixed-HDF, clinical studies testing the efficacy of mixed-
HDF versus pre- or postdilution HDF are lacking. Several 
studies have reported that the efficiencies of small- or large-
sized molecule removal between mixed-HDF and pre- or 
postdilution HDF are comparable. Also, TMP is maintained 
at a more stable level in mixed-HDF compared with postdi-
lution HDF [13–15]. In parts of East Asia such as Japan, most 
HD units tend to use predilution HDF due to intrinsic prob-
lems with postdilution HDF, including high TMP and the 
tendency to promote clot formation [11,16]. This is also true 
in Korea, where utilization of predilution HDF is increasing 
[8]. However, whether mixed-HDF performs well in compar-
ison to predilution HDF remains unknown. Therefore, we 
conducted a randomized controlled trial to compare predi-
lution HDF with mixed-HDF in Korean patients with KFRT. 
Methods 
Study design and participants 
This study was a prospective, randomized, open-label trial 
conducted at two hospitals in Korea (Severance Hospi-
tal, Seoul; National Health Insurance Service [NHIS] Ilsan 
Hospital, Goyang). Individuals aged 20 to 75 years who had 
received HD 3 times weekly for ≥3 months were allowed to 
participate in the study. Exclusion criteria were as follows: 
(1) life expectancy < 12 months, (2) dialysis treatment re-
ceived for less than 3 months or initiated due to acute kidney 
injury, (3) current history of malignancy, (4) pregnancy, (5) 
contraindication to anticoagulants, (6) systemic blood pres-
sure < 90 mmHg, and (7) previously received HDF before 
enrollment. The study was conducted in accordance with 
the principles of the Declaration of Helsinki, and the study 
protocol was approved by the Institutional Review Board at 
each center (No. 4-2016-0702 for Severance Hospital; No. 
2018-11-002 for NHIS Ilsan Hospital). All participants pro-
vided informed consent when enrolled in the study.  
Between January 2017 and December 2019, a total of 66 
patients was screened. After a 1-month screening period, 
60 patients were randomly assigned at a 1:1 ratio to receive 
either mixed-HDF or predilution HDF for 6 months. The 
random assignment was performed using a web-based, 
random allocation table that considered institution, sex, and 
causative disease of KFRT (Fig. 1). 
Treatment procedures 
All participants received thrice-weekly dialysis for at least 
3 hours. Both groups were treated with the 5008 or 5008S 
dialysis system using CorDiax dialyzer (Fresenius Medical 
Care, Bad Homburg, Germany) and maintained a blood 
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flow rate of 250 mL/min and dialysate flow rate of 700 mL/
min. TMP was not expected to exceed 400 mmHg in either 
predilution HDF or mixed-HDF patients. Prescribed ul-
trafiltration rate and substitution fluid in both predilution 
and mixed-HDF groups were calculated using previously 
reported equations [17]. 
Study variables 
The demographic and medical history of participants was 
collected at enrollment. We recorded dialysis-related infor-
mation at baseline and every 3 months thereafter. Informa-
tion collected included dialyzer characteristics, dialysis time, 
dialysis machine, blood and dialysate flows, substitution 
volume, TMP, height, dry body weight, pre- and postdialysis 
body weight, delivered convective volume, net ultrafiltration 
volume, and predialysis systolic and diastolic blood pres-
sure. Further, the following laboratory data were measured 
at 0, 3, and 6 months after initiation of this research: hemo-
globin, hematocrit, white blood cell differential count, plate-
let count, predialysis urea concentration, creatinine, sodium, 
potassium, concentration of bicarbonate using total carbon 
dioxide, calcium, phosphate, intact parathyroid hormone, 
high-sensitivity C-reactive protein (hs-CRP), albumin, and 
fasting glucose. To determine the reduction ratio (RR) of 
β2-microglobulin at pre-and postdialysis, serum β2-micro-
globulin level was measured at 0 and 6 months. All laborato-
ry tests were performed locally using standard procedures in 
certified laboratories. The RR of β2-microglobulin was cal-
culated using pre- and postdialysis serum β2-microglobulin 
levels and the following formula: RR (%) = [1 − (concentration 
of serum β2-microglobulin obtained after dialysis/concen-
tration of serum β2-microglobulin obtained before dialysis)] 
× 100. Extracellular fluid and total body water volumes were 
measured via multiple frequency bioelectrical impedance 
analysis (BCM; Fresenius Medical Care). Measured extra-
cellular fluid volume is presented as overhydrated (L). Mea-
sured relative extracellular fluid volume considering total 
body water fluid volume is presented as overhydrated-extra-
cellular fluid (%). 
Outcomes 
The primary outcome assessed was the delivered convec-
tion volume difference between mixed-HDF and predilution 
HDF treatment methods [18]. Since the predilution mode of 
therapy used twice as much replacement fluid as the post-
dilution mode, we calculated effective convection volume 
ratios for mixed-HDF as follows: effective convection vol-
ume = substitution volume in predilution mode + 2 × substi-
tution volume in postdilution mode + ultrafiltration volume. 
In addition, we compared convection volume adjusted for 
body surface area between two groups. Secondary outcomes 
included middle- (RR of β2-microglobulin) and small-sized 
Figure 1. A flow chart of the study population that includes the numbers of patients who were screened, underwent randomization, 
and completed the assessment. 
HDF, hemodiafiltration.
66 Patients were screened for eligibility
60 Underwent randomization
27 Had completed the study 26 Had completed the study
6 Declined to participate
3 Withdrawls
- Hospitalization: 1
- Refused to continue the study: 2
4 Withdrawls
- Hospitalization: 2
- Refused to continue the study:2
30 Were assigned to receive predilution HDF 30 Were assigned to receive mixed-HDF
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molecule clearance (Kt/V urea), changes in predialysis levels 
of an inflammatory marker (hs-CRP) and phosphate, TMP, 
blood pressure, and intradialysis tolerance. 
Power calculation 
The total substitution fluid volume is always greater when 
using predilution HDF versus mixed-HDF. Because mixed-
HDF uses both pre- and postdilution modes during the di-
alysis session, we hypothesized that the effective convective 
volume in mixed-HDF would be 120% of that of predilution 
HDF, and the difference in convective fluid would be ap-
proximately 7.5 L, which was used as a noninferiority limit. 
Thus, it was determined that 25 patients within each group 
were needed to detect a 10-L delivered convective volume 
difference between the two groups assessed with a power of 
90% and an α-value of 0.05. Considering a dropout percent-
age of 20%, the number needed per group was 30 patients. 
Statistical analyses 
All data were analyzed according to the per-protocol princi-
ple. Data are expressed as mean ± standard deviation or as 
median (range) for skewed data. Baseline clinical data and 
laboratory findings, measured at the time of random group 
assignment, were compared using the t-test and chi-square 
test. In addition, changes in primary and secondary out-
come parameters were analyzed using repeated measures 
analysis of variance (ANOVA). Continuous variables were 
assessed using a mixed model approach for repeated mea-
surements, after adjustment for age, sex, serum albumin and 
hemoglobin levels, systolic blood pressure (SBP), predialysis 
serum β2 microglobulin concentration, and dialysis blood 
flow. A two-sided significance test was used throughout the 
analysis, and values of p < 0.05 were considered significant. 
All statistical analyses were performed using the STATA ver-
sion 16 statistical package (StataCorp, College Station, TX, 
USA). 
Results 
Baseline patient characteristics 
The baseline characteristics of patients and treatment pa-
rameters are summarized in Table 1. The mean age was 59.7 
years, and 50.9% of study participants were male. All pa-
tients had been on dialysis treatment for 2 years (range, 1–4 
years). Overall, there were no differences in baseline char-
acteristics observed between the two groups. However, the 
serum β2-microglobulin level of the mixed-HDF group was 
significantly higher than that of the predilution HDF group. 
Among dialysis parameters, dialysis time, TMP, dialysis flow 
rate, and net ultrafiltration did not differ between the two 
groups. However, the mixed-HDF group had slightly lower 
blood flow rate than the predilution HDF group. 
Primary outcome 
Table 2 and Supplementary Fig. 1A (available online) show 
convection volumes of the two HDF groups during the 
6-month period considered. In the predilution HDF group, 
the mean convective volume determined by averaging val-
ues from three time points was 41.0 ± 10.3 L/session, and 
the convective volume was constantly delivered during fol-
low-up. In the mixed-HDF group, the switch to predilution 
mode was successfully accomplished depending on TMP 
level during the dialysis session. In this group, the total effec-
tive convection volume delivered was 51.5 ± 9.0 L/session in 
the mixed-HDF group, which was approximately 20% higher 
than that of the predilution HDF group. The difference in ef-
fective convection volume between the two groups was 10.5 
± 1.3 L/ session, which met our preset noninferiority criteria 
(Fig. 2B, Supplementary Fig. 1B). This finding suggests that 
mixed-HDF is comparable to predilution HDF with respect 
to convection volume. Repeated ANOVA analysis and linear 
mixed model assessment also showed that effective convec-
tion volume was greater in the mixed-HDF group than in the 
predilution HDF group throughout the study period. These 
results were similar when body surface area-adjusted vol-
umes were compared (Table 2 and Fig. 2). 
Secondary outcomes 
In secondary outcome analyses, we first compared middle- 
and small-molecule clearance rates of mixed-HDF and 
predilution HDF groups. The predialysis serum β2-micro-
globulin level was significantly higher in the mixed-HDF 
group than the predilution HDF group during the study pe-
riod. However, serum β2-microglobulin level of the mixed-
HDF group significantly decreased from the baseline value 
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(25.4 ± 5.6 mg/L to 22.2 ± 4.4 mg/L), while they remained 
relatively constant in the predilution HDF group at the 
same time period (p for intergroup difference = 0.02) (Ta-
ble 3, Supplementary Fig. 2A). The β2-microglobulin RRs 
Table 1. Baseline characteristics
Variable Predilution HDF (n = 27) Mixed-HDF (n = 26) p-value
Age (yr) 59.0 ± 1.3 60.5 ± 1.1 0.63
Male sex 16 (59.3) 11 (42.3) 0.22
Body mass index (kg/m2) 23.7 ± 3.4 22.6 ± 3.9 0.25
Diabetes mellitus 16 (59.3) 14 (53.8) 0.69
Cerebrovascular disease 10 (37.0) 4 (15.4) 0.07
Cardiovascular disease 12 (44.4) 10 (38.5) 0.66
CCI 2 (2–3) 3 (2–3) 0.14
Cause of KFRT
 Diabetes mellitus 16 (59.3) 12 (46.2) 0.46
 Hypertension 9 (33.3) 10 (38.5)
 Glomerulonephritis 1 (3.7) 3 (11.5)
 Others 1 (3.7) 1 (3.8)
BP-lowering drug 23 (85.2) 21 (80.8) 0.67
 ARB 17 (63.0) 17 (65.4) 0.85
 CCB 11 (40.7) 14 (53.8) 0.34
 β-Blocker 12 (44.4) 15 (57.7) 0.34
 α-Blocker 3 (11.1) 6 (23.1) 0.25
SBP (mmHg) 147.0 ± 25.7 148.1 ± 22.6 0.87
DBP (mmHg) 73.5 ± 17.4 72.8 ± 13.9 0.86
Hemoglobin (g/dL) 10.6 ± 1.1 10.2 ± 1.3 0.32
Albumin (g/dL) 3.9 ± 0.3 3.9 ± 0.3 0.57
hs-CRP (mg/dL) 0.7 (0.11–1.4) 0.8 (0.23–1.5) 0.87
Sodium (mmol/L) 137.7 ± 2.8 134.0 ± 17.7 0.29
Potassium (mmol/L) 5.1 ± 0.7 4.9 ± 0.7 0.35
Bicarbonate (mmol/L) 23.6 ± 4.6 23.8 ± 2.6 0.89
PTH (pg/mL) 255.5 (188.7–395.6) 265.8 (169.6–451.9) 0.75
Calcium (mg/dL) 8.6 ± 1.3 8.9 ± 0.6 0.26
Phosphate (mg/dL) 5.4 ± 1.8 5.2 ± 1.3 0.73
BUN (mg/dL) 62.1 ± 15.8 58.8 ± 16.8 0.47
Creatinine (mg/dL) 10.1 ± 2.4 10.0 ± 4.4 0.88
B2MG (mg/L) 21.7 (19.7–23.4) 25.6 (21.4–28.0) 0.006
Glucose (mg/dL) 138.6 ± 58.9 132.2 ± 73.2 0.73
Dialysis parameter
 Vintage (yr) 1.5 (1.0–4.25) 3 (1–4) 0.89
 Dialysis time (min) 241.0 ± 0.9 241.6± 2.5 0.52
 TMP (mmHg) 150.2 ± 47.6 162.5 ± 51.2 0.37
 Blood flow (mL/min) 272.8 ± 39.7 256.2 ± 31.8 0.005
 Heparin dose (IU/session) 2,205.6 (1,201.7–2,213.9) 1,899.4 (1,603.3–2,209.5) 0.48
 Dialysate flow (mL/min) 607.0 ± 90.5 589.5 ± 113.3 0.54
 Net ultrafilation (L/sesseion) 2.3 ± 1.0 2.3 ± 1.1 0.91
Data are expressed as mean ± standard deviation, number (%), or median (interquartile range).
ARB, angiotensin receptor blocker; B2MG, β2-microglobulin; BP, blood pressure; BUN, blood urea nitrogen; CCB, calcium channel blocker; CCI, Charlson 
comorbidity index; DBP, diastolic blood pressure; HDF, hemodiafiltration; hs-CRP, high-sensitivity C-reactive protein; KFRT, kidney failure with replacement 
therapy; PTH, parathyroid hormone; SBP, systolic blood pressure; TMP, transmembrane pressure.
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at baseline did not differ between the two groups (75.2% ± 
4.9% in the predilution HDF group vs. 76.0% ± 4.8% in the 
mixed-HDF group). The RR significantly decreased in the 
predilution HDF group at 6 months, whereas it increased in 
the mixed-HDF group (p for intergroup difference = 0.01) 
(Table 3, Fig. 3). Kt/V urea values, used as a traditional index 
for small-molecule clearance, were similar between the two 
groups throughout the study period (Table 3, Supplementary 
Fig. 2B). We also monitored TMP level during dialysis ses-
sions because the mixed-HDF technique involves switching 
of HDF mode based on TMP level. The mixed-HDF group 
had consistently higher TMP level compared to the predilu-
tion HDF group during the 6-month study period (p for inter-
group difference = 0.001) (Table 3, Supplementary Fig. 2C). 
During the study period, there were no significant be-
tween-group differences in terms of serum hs-CRP, al-
bumin, phosphate, sodium, potassium, and bicarbonate 
concentrations (Table 3). Out of 53 patients, 47 had avail-
able bioimpedance analysis data. As shown in Table 3, the 
proportions of overhydration status did not differ between 
the groups. 
At baseline, SBP for the predilution HDF and mixed-HDF 
groups were 147 ± 25.7 and 148.1 ± 22.6 mmHg, respective-
ly. SBP increased at 3 months relative to baseline but then 
decreased at 6 months relative to the increase observed at 
3 months in both groups. The difference observed between 
the two groups did not reach statistical significance. DBP 
of both groups remained similar throughout the 6-month 
study period (Table 3). Most patients tolerated HDF therapy 
well, and the symptomatic adverse event rate was remark-
ably low. The most common adverse effect observed was an 
asymptomatic decrease in SBP by >10 mmHg during a dial-
ysis session, which occurred in 44% of all patients. However, 
symptomatic intradialytic hypotension was rarely observed 
in either group (3.7% versus 1.3% in predilution and mixed-
HDF, respectively). There were no differences in any other 
event rates observed between the two groups (Table 4). 
Discussion 
In this randomized controlled study, we demonstrated that 
mixed-HDF therapy produces outcomes similar to predi-
lution HDF. Convective volume was delivered well in the 
mixed-HDF group, and the difference in effective convec-










 Absolute Predilution 41.0 ± 10.3 40.4 ± 8.0 39.1 ± 8.7 44.0 ± 13.1 0.17
Mixed 35.0 ± 5.7 32.6 ± 7.8 36.3 ± 4.2 36.1 ± 3.7 <0.001 0.01
 Effective Predilution 41.0 ± 10.3 40.4 ± 8.0 39.1 ± 8.7 44.0 ± 13.1 0.17
Mixed 51.5 ± 9.0 47.9 ± 10.4 53.3 ± 7.6 53.2 ± 7.4 <0.001 0.003
Substitution volume (L/session)
 Via predilution mode Predilution 38.8 ± 10.5 37.7 ± 8.0 36.8 ± 8.9 41.8 ± 13.4 0.16
Mixed 16.6 ± 4.2 15.6 ± 6.8 17.1 ± 2.3 17.1 ± 2.1 0.44
 Via postdilution mode Predilution NA NA NA NA
Mixed 16.3 ± 2.5 14.8 ± 2.6 16.9 ± 2.2 17.1 ± 2.1 <0.001
Net ultrafiltration (L/session) Predilution 2.3 ± 1.1 2.3 ± 1.0 2.3 ± 1.1 2.2 ± 1.1 0.72
Mixed 2.2 ± 1.1 2.3 ± 1.1 2.3 ± 1.0 1.9 ± 1.1 0.73 0.06
Convection volumes adjusted for  
body surface area (L/m2 per session)
 Absolute Predilution 24.5 ± 3.8 24.4 ± 5.1 23.1 ± 5.5 25.8 ± 7.8 0.27
Mixed 20.6 ± 5.5 18.0 ± 5.1 20.0 ± 4.1 23.8 ± 10.5 0.004 0.004
 Effective Predilution 24.5 ± 3.8 24.4 ± 5.1 23.1 ± 5.5 25.8 ± 7.8 0.60
Mixed 31.5 ± 5.3 27.5 ± 5.4 32.6 ± 4.6 34.4 ± 11.2 <0.001 0.003
Data are presented as mean ± standard deviation. 
All analyses were conducted using repeated measures analysis of variance.
HDF, hemodiafiltration; NA, not available.
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Figure 2. Changes and difference in effective convection volume. (A) Effective convection volume over 6 months (p for intergroup 
difference < 0.001). (B) Noninferiority of mixed-HDF compared with predilution HDF. The gray line indicates predilution HDF, and the 
black line indicates mixed-HDF.
HDF, hemodiafiltration.
Figure 3. Changes in reduction ratios of B2MG during the 
study period (p for intergroup difference = 0.01). The yellow line 
indicates predilution HDF, and the red line indicates mixed-HDF. 
HDF, hemodiafiltration; B2MG, β2-microglobulin.
tion volume met noninferiority criteria. We also showed that 
mixed-HDF more efficiently decreased β2-microglobulin 
circulating level compared with predilution HDF. There 
were no differences in removal rates of small molecules, nor 
were other clinical or biochemical parameter differences 
observed during the study period. All adverse events were 
minor and occurred similarly in the two groups. These find-
ings suggest that mixed-HDF is comparable to predilution 
HDF with regard to convection volume delivery, and that it 
removes middle molecules more efficiently. 
HDF has been established as effective dialysis therapy, 
and its use has many advantages over conventional HD. 
These include higher clearance of middle molecular weight 
uremic toxins, better maintenance of hemodynamic stabil-
ity, greater removal of inflammatory cytokines, and better 
responsiveness to erythropoietin [19,20]. Several random-
ized controlled trials have demonstrated that HDF reduces 
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Table 3. Secondary outcome analysis
Variable Treatment
Observed data p-value
Mean value of 





Predialysis B2MG (mg/L) Predilution 21.2 ± 4.8 21.5 ± 3.5 21.2 ± 6.3 20.9 ± 4.5 0.88
Mixed 23.6 ± 4.7 25.4 ± 5.6 23.3 ± 3.6 22.2 ± 4.4 0.02 0.004
Reduction ratio of B2MG (%) Predilution 73.9 ± 6.6 75.2 ± 4.9 NA 72.8±7.9 0.36
Mixed 76.5 ± 5.9 76.0 ± 4.8 NA 78.7±5.1 0.01 0.02
Kt/V urea Predilution 1.53 ± 0.2 1.53 ± 0.3 1.49 ± 0.2 1.57 ± 0.2 0.37
Mixed 1.56 ± 0.3 1.51 ± 0.3 1.59 ± 0.25 1.57 ± 0.3 0.33 0.19
TMP (mmHg) Predilution 139.6 ± 42.0 150.2 ± 47.6 135.7 ± 36.9 132.9 ± 40.3 0.09
Mixed 176.2 ± 51.9 162.5 ± 51.2 192.7 ± 42.4 173.1 ± 59.1 0.001 0.06
hs-CRP (mg/dL) Predilution 0.6 (0.1–1.7) 0.7 (0.1–1.4) 0.6 (0.2–2.2) 0.6 (0.1–3.3) 0.14
Mixed 0.9 (0.3–2.0) 0.8 (0.2–1.5) 1.1 (0.3–2.0) 0.9 (0.3–3.5) 0.82 0.82
Albumin (g/dL) Predilution 3.9 ± 0.3 3.9 ± 0.3 4.0 ± 0.4 3.9 ± 0.3 0.14
Mixed 3.8 ± 0.4 3.9 ± 0.3 3.8 ± 0.4 3.8 ± 0.4 0.16 0.14
Phosphate (mg/dL) Predilution 5.1 ± 1.7 5.4 ± 1.8 5.0 ± 1.4 4.8 ± 1.7 0.30
Mixed 5.0 ± 1.4 5.2 ± 1.3 4.9 ± 1.5 4.8 ± 1.3 0.79 0.29
Sodium (mmol/L) Predilution 137.7 ± 4.2 137.7 ± 2.9 138.3 ± 3.1 137.2 ± 6.0 0.51
Mixed 137.3 ± 3.5 137.9 ± 4.3 136.7 ± 3.3 137.3 ± 2.7 0.59 0.19
Potassium (mmol/L) Predilution 5.0 ± 0.8 5.1 ± 0.7 5.0 ± 0.8 4.9 ± 0.8 0.49
Mixed 5.0 ± 0.7 4.9 ± 0.7 4.9 ± 0.8 5.2 ± 0.6 0.91 0.13
Bicarbonate (mmol/L) Predilution 23.4 ± 4.0 23.6 ± 4.6 23.4 ± 3.5 23.3 ± 3.9 0.81
Mixed 23.4 ± 3.0 23.8 ± 2.6 23.4 ± 3.7 22.9 ± 2.8 0.89 0.13
Bioimpedance parameter
 OH (L) Predilution 0.8 (–0.9 to 1.2) NA 1.0 (–0.3 to 2.7) >0.99
Mixed 0.3 (–0.2 to 1.23) NA 0.7 (–0.6 to 2.9) 0.32 0.16
 OH-ECW (%) Predilution 4.5 (–5.6 to 9.1) NA 7.1 (–1.9 to 14.6) 0.98
Mixed 2.7 (–1.2 to 8.0) NA 4.1 (–4.5 to 18.2) 0.33 0.16
Predialysis blood pressure (mmHg)
 SBP Predilution 147.0 ± 25.7 155.8 ± 25.5 149.2 ± 26.0 0.14
Mixed 148.1 ± 22.6 156.1 ± 24.7 153.9 ± 28.8 0.74 0.22
 DBP Predilution 73.5 ± 17.2 74.0 ± 14.6 73.9 ± 18.6 >0.99
Mixed 72.8 ± 13.9 74.9 ± 15.9 74.1 ± 13.4 0.97 0.68
Data are presented as mean ± standard deviation or median (interquartile range).
B2MG, β2-microglobulin; DBP, diastolic blood pressure; hs-CRP, high-sensitive C-reactive protein; NA, not available; OH-ECW, overhydration/extracellular 
water; OH, overhydration; SBP, systolic blood pressure; TMP, transmembrane pressure. 
All analyses were conducted using repeated measures analysis of variance.
pared with conventional HD when an optimal convective 
substitution fluid was used [21–25]. Such proven benefits 
have resulted in the increased utilization of HDF in Euro-
pean countries [26]. There have been remarkable advances 
in HDF techniques, and several HDF methods have been 
implemented in clinical practice, including predilution, 
postdilution, and mixed modes. Most trials to date have test-
ed the effects of postdilution HDF, and studies on other HDF 
modes are lacking. Interestingly, in East Asian countries, 
predilution HDF with a low access blood flow rate has been 
widely used [8]. A recently published observational study in 
Japan, where predilution HDF is preferred in most centers, 
suggested that this HDF mode was significantly associated 
with improved overall and cardiovascular survival compared 
with conventional HD [27]. 
Both pre- and postdilution HDF modes have pros and 
cons. Although the postdilution HDF mode, which is being 
recommended to most patients in Western countries, is as-
sociated with a highly efficient clearance of uremic toxins 
with a relatively small substitution volume, the limitation of 
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the method is that blood flow should be maintained at a cer-
tain speed to reduce risk of blood clot formation. Patients in 
East Asian countries, who have relatively low blood flow of 
arteriovenous access, prefer predilution HDF mode to post-
dilution HDF, due to lower risk of clotting events in the for-
mer mode [6]. Recently, a new mode called mixed-HDF was 
developed to address the drawbacks of pre- and postdilution 
HDF. Mixed-HDF monitors optimal TMP and automatically 
switches to pre- or postdilution mode when the TMP level 
reaches a particular threshold, before a clotting issue occurs 
[15,28]. This process can compensate for the weaknesses of 
each HDF mode. Although few studies have compared the 
efficacy of mixed-HDF versus other HDF modes, Pedrini 
and De Cristofaro [2] reported that mixed-HDF had a better 
β2-microglobulin removal rate than postdilution HDF. In 
addition, de Sequera et al. [29] showed that mixed-HDF was 
comparable to postdilution HDF with regard to small and 
medium-sized and protein-bound molecule clearance. 
Delivered convective volume is considered a crucial 
factor that influences HDF therapy. Mixed-HDF is a new 
concept of high-efficiency HDF in which predilution and 
postdilution modes are mixed, and it is difficult to compare 
quantitatively absolute substitution fluid with those of the 
predilution mode. Given that a greater volume of substitu-
tion fluid is required in predilution mode versus postdilu-
tion HDF mode, we developed the concept of using effective 
convection volume for quantitative comparison between 
the two groups. Since the predilution mode of HDF uses 
twice as much replacement fluid as does postdilution mode, 
we hypothesized that the effective convection volume via 
mixed-HDF mode consisted of a sum of the substitution vol-
ume in postdilution mode times two, substitution volume in 
predilution mode, and ultrafiltration volume. Although the 
absolute convection volume was higher in predilution HDF, 
we showed that the effective convection volume delivered 
by mixed-HDF was greater than that of predilution HDF. The 
effective convection volume from mixed-HDF was approx-
imately 20% higher than that of predilution HDF. The opti-
mal convection volume delivered by mixed-HDF remains 
unknown because no studies have yet examined mixed-
HDF outcomes such as mortality or cardiovascular events 
based on convection volume. In this regard, the concept of 
effective convection volume might be an alternative tool for 
the comparison of convection volumes for predilution and 
mixed-HDF. Notably, differences in effective convection vol-
ume might result in improved β2-microglobulin clearance 
by mixed-HDF. This is important because the accumulation 
of middle molecules, such as β2-microglobulin, is an inde-
pendent predictor of mortality [30–32], and β2-microglob-
ulin clearance correlates well with convection volume [33]. 
In addition, dialysis tolerance of patients was similar for the 
two HDF modes. All adverse events were minor, and the 
event rates of both groups were similar. Taken together, these 
findings suggest that mixed-HDF can be an alternative dial-
ysis tool for patients who frequently experience dialysis-re-
lated symptoms such as intradialysis hypotension, muscle 
cramping, and arrhythmia [25]. 
This study has limitations. First, the sample size was small, 
Table 4. Adverse event rates
Variable Predilution HDF (n = 81) Mixed-HDF (n = 78) p-value
No. of adverse events 42 (51.9) 40 (51.3) 0.94
At least one event
A decrease in SBP >10 mmHg without symptoms 36 (44.4) 34 (43.6) 0.73
Symptomatic intradialytic hypotensiona 3 (3.7) 1 (1.3)
Headache 1 (1.2) 2 (2.6)
Muscle cramps 2 (2.5) 1 (1.3)
Nausea, vomiting 0 1 (1.3)
Fever 0 1 (1.3)
Chest pain 0 0
Arrhythmia 0 0
Data are presented as number (%). The percentages were calculated with number of adverse events per dialysis sessions during study period. 
HDF, hemodiafiltration; SBP, systolic blood pressure.
aSymptomatic intradialytic hypotension is defined as a decrease in SBP by ≥20 mmHg associated with symptoms that include abdominal discomfort, 
yawning, sighing, nausea, vomiting, muscle cramps, restlessness, dizziness or fainting, and anxiety.
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and only two centers participated. Therefore, selection bias 
could not be excluded. Second, we could not determine op-
timal convection volume. It should be noted that many pre-
vious trials with postdilution HDF consistently showed im-
proved patient survival rate compared with conventional HD 
in patients with adequately delivered convection volume. 
To date, there has been no randomized controlled trial that 
has assessed the delivered convection volume in patients 
given predilution HDF or mixed-HDF therapy. Future stud-
ies with larger sample sizes will be needed to address this. 
Third, we measured β2-microglobulin and hs-CRP levels as 
representative middle molecule and inflammatory markers, 
although other uremic toxins with deleterious effects exist. 
Because the predilution mode has an intrinsic limitation in 
the degree of clearance compared with postdilution HDF, 
the performance of mixed-HDF should be further tested 
using other molecules. Fourth, we used a simple equation of 
RR of β2-microglobulin, which was not calibrated for body 
fluid reduction during dialysis. However, as there was no 
significant difference in ultrafiltration volume between the 
predilution and mixed-HDF groups, ultrafiltration volume 
is unlikely to alter the outcomes. Finally, we did not evaluate 
albumin loss via dialyzer during the study. Albumin loss via 
HDF can differ depending on the dialyzer, dialysis modali-
ties, and convection volumes. Previous studies have report-
ed a wide range of albumin loss between 0.5 and 4.5 g per 
session in postdilution HDF [34–36]. The amount of albumin 
loss in mixed-HDF is not well known. Although albumin 
loss is less severe in predilution HDF than in postdilution 
HDF, albumin loss via HDF can be especially important for 
patients with marked hypoalbuminemia. However, in this 
study, the two groups used the same dialyzer that has a very 
low albumin-sieving coefficient according to the manufac-
turer. Moreover, serum albumin levels were comparable 
between the two groups. Thus, albumin loss was unlikely to 
affect the study results. 
In conclusion, we demonstrated that mixed-HDF per-
formed well with regard to convective volume delivery and 
provided better middle molecule clearance than predilu-
tion HDF. For the implementation of mixed-HDF in clinical 
practice, further studies should explore whether the use of 
mixed-HDF is advantageous over other dialysis modes with 
regard to its cost-effectiveness and long-term outcomes. 
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